naxitamab
naxitamab: 5 clinical trials tracked.
naxitamab evidence translation
What we can confirm
5 tracked trials
What it means
What to watch
Prepared research question
What is verified about naxitamab, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Clinical Trial Registry Records (5)
Phase II Trial of Naxitamab, Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Combination With Induction Chemotherapy for Patients With Newly-Diagnosed High-Risk Neuroblastoma
Primary endpoint: Evaluate the safety of chemoimmunotherapy with Naxitamab and COG-type induction chemotherapy in newly diagnosed patients with high-risk neuroblastoma
Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
Primary endpoint: Safety and Adverse Events (AEs)
Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma
Primary endpoint: Recommended duration of naxitamab infusion
N10: Reduced Therapy for High-Risk Neuroblastoma
Primary endpoint: Evaluate participant response
A Phase II Study of Naxitamab Added to Induction Therapy for Subjects With Newly Diagnosed High-Risk Neuroblastoma
Primary endpoint: Number of participants with Complete Response (CR) rate per 1993 INRC guidelines